Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656053 | 0.87 | KDM4E (0.51) | ALDH1A1HPGDKDM4ENPSR1CLK1 | |
| SCHEMBL6605993 | 0.87 | LMNA (0.45) | ALDH1A1HPGDKDM4ENPSR1NCEH1 | |
| SCHEMBL6603583 | 0.87 | ALDH1A1 (0.42) | ALDH1A1HPGDKDM4ENPSR1NCEH1 | |
| SCHEMBL4656172 | 0.86 | HPGD (0.43) | ALDH1A1HPGDKDM4ENPSR1SMN1; SMN2 | |
| SCHEMBL10699646 | 0.84 | NCEH1 (0.44) | ALDH1A1HPGDKDM4ENPSR1NCEH1 | |
| SCHEMBL4676934 | 0.84 | MEN1 (0.45) | ALDH1A1HPGDKDM4ENPSR1NCEH1 | |
| SCHEMBL6510652 | 0.84 | NCEH1 (0.44) | ALDH1A1HPGDKDM4ENPSR1NCEH1 | |
| SCHEMBL6606670 | 0.83 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4ENPSR1NCEH1 | |
| SCHEMBL4673550 | 0.82 | NCEH1 (0.39) | ALDH1A1HPGDKDM4ENPSR1NCEH1 | |
| SCHEMBL6603195 | 0.81 | POLB (0.42) | ALDH1A1HPGDKDM4ENPSR1NCEH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6963011-B2 | N-(2-phenyl-3-aminopropyl)naphthamides | ASTRAZENECA AB (SE) | 2005-11-08 | — | — | US | disclosed |
| EP-1278719-B1 | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| US-6903092-B2 | Naphthamide neurokinin antagonists for use as medicaments | ASTRAZENECA AB (SE) | 2005-06-07 | — | — | US | disclosed |
| EP-1307425-B1 | NOVEL N-(2-PHENYL-3-AMINOPROPYL)NAPHTAMIDES | ASTRAZENECA AB (SE) | 2005-04-20 | — | — | EP | disclosed |
| EP-1119551-B1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| US-6821973-B2 | ANTAGONIZE THE PHARMACOLOGICAL ACTIONS OF THE ENDOGENOUS NEUROPEPTIDE TACHYKININS KNOWN AS NEUROKININS | ASTRAZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| EP-1169302-B1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| EP-1433783-A2 | Naphthalenecarboxamides as tachykinin receptor antagonists | AstraZeneca AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-20040106610-A1 | Compounds | BERNSTEIN PETER ROBERT (US) | 2004-06-03 | — | — | US | disclosed |
| US-20040014809-A1 | Novel n-( 2-phenyl-3-aminopropyl)naphtamides | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | US | disclosed |
| US-6500818-B1 | Naphthalenecarboxamides as tachykinin receptor antagonists | ASTRAZENECA AB (SE) | 2002-12-31 | — | — | US | disclosed |
| US-6476077-B1 | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | ASTRAZENECA AB (SE) | 2002-11-05 | — | — | US | disclosed |
| WO-2002012168-A1 | NOVEL N-(2-PHENYL-3-AMINOPROPYL)NAPHTAMIDES | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1169302-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| WO-2001077069-A1 | NAPHTHAMIDE NEUROKININ ANTAGONISTS FOR USE AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| EP-1119551-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| EP-1119355-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000059873-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000020003-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020389-A1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106610-A1 | Compounds | NR2C2, NR0B2, NR5A2 | ALDH1A1 2538/4885HPGD 3657/4885KDM4E 2462/4885 |
| US-20040014809-A1 | Novel n-( 2-phenyl-3-aminopropyl)naphtamides | NPSR1, NTSR1, NPR1 | ALDH1A1 1696/4885HPGD 1034/4885KDM4E 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.